0000899243-22-034377.txt : 20221027 0000899243-22-034377.hdr.sgml : 20221027 20221027215011 ACCESSION NUMBER: 0000899243-22-034377 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221025 FILED AS OF DATE: 20221027 DATE AS OF CHANGE: 20221027 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harrison Seth Loring CENTRAL INDEX KEY: 0001404955 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 221338846 MAIL ADDRESS: STREET 1: 230 PARK AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-25 0 0001744659 Akero Therapeutics, Inc. AKRO 0001404955 Harrison Seth Loring C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2022-10-25 4 S 0 4515 44.9163 D 300851 D Common Stock 2022-10-25 4 S 0 4906 44.9163 D 326813 I See Footnote Common Stock 2022-10-26 4 S 0 35860 43.0756 D 264991 D Common Stock 2022-10-26 4 S 0 11539 43.9749 D 253452 D Common Stock 2022-10-26 4 S 0 18486 44.9002 D 234966 D Common Stock 2022-10-26 4 S 0 38961 43.0756 D 287852 I See Footnote Common Stock 2022-10-26 4 S 0 12537 43.9749 D 275315 I See Footnote Common Stock 2022-10-26 4 S 0 20085 44.9002 D 255230 I See Footnote Common Stock 2022-10-27 4 S 0 40903 41.1156 D 194063 D Common Stock 2022-10-27 4 S 0 21830 42.0299 D 172233 D Common Stock 2022-10-27 4 S 0 3693 43.2321 D 168540 D Common Stock 2022-10-27 4 S 0 44440 41.1156 D 210790 I See Footnote Common Stock 2022-10-27 4 S 0 23719 42.0299 D 187071 I See Footnote Common Stock 2022-10-27 4 S 0 4013 43.2321 D 183058 I See Footnote The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4. The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution"). (Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution. Represents shares held directly by the LLC. The reporting person is the manager of the LLC. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.635 to $45.14, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.715, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.72 to $42.715, inclusive. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.495, inclusive. /s/ Jonathan Young, attorney-in-fact 2022-10-27